GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A3166 AM0953 CitationSummary: Potent LPA1 receptor antagonist
-
A3167 AM-095 free baseTarget: LPA ReceptorsSummary: Potent LPA1 receptor antagonist
-
A3170 AM9662 CitationTarget: LPA ReceptorsSummary: LPA1 antagonist, oral active, high affinity, selective,
-
B1591 Ki16198Target: LPA ReceptorsSummary: LPA antagonist
-
A1987 Ki164254 CitationTarget: LPA ReceptorsSummary: LPA receptor antagonist
-
B7818 ONO-7300243Target: LPASummary: LPA1 antagonist
-
C3497 DBIBBSummary: LPA2 agonist
-
C3343 Tetradecyl PhosphonateSummary: pan-antagonist of lysophosphatidic acid 1 (LPA1), LPA2, and LPA3 receptors
-
B5689 TC LPA5 4Summary: LPA5 receptor antagonist
-
B5744 H2L 5765834Summary: lysophosphatidic acid receptors antagonist